In Vitro Co-Delivery Evaluation of Novel Pegylated
Nano-Liposomal Herbal Drugs of Silibinin and
Glycyrrhizic Acid (Nano-Phytosome) to
Hepatocellular Carcinoma Cells
This study aimed to evaluate a co-encapsulated pegylated nano-liposome system based on two herbal anti-tumor drugs, silibinin and glycyrrhizic acid, for delivery to a hepatocellular carcinoma (HCC) cell line (HepG2).
Materials and Methods
In this experimental study, co-encapsulated nano-liposomes by the thin layer film hydration method with HEPES buffer and sonication at 60% amplitude. Liposomes that co-encapsulated silibinin and glycyrrhizic acid were prepared with a specified molar ratio of dipalmitoylphosphatidylcholine (DPPC), cholesterol (CHOL), and methoxy-polyethylene glycol 2000 (PEG2000)–derived distearoyl phosphatidylethanolamine (mPEG2000-DSPE). We used the MTT technique to assess cytotoxicity for various concentrations of co-encapsulated nano-liposomes, free silibinin (25% w/v) and glycyrrhizic acid (75% w/v) on HepG2 and fibroblast cell lines over a 48-hour period.
Formulation of pegylated nano-liposomes showed a narrow size distribution
with an average diameter of 46.3 nm. The encapsulation efficiency (EE) for silibinin was
24.37%, whereas for glycyrrhizic acid it was 68.78%. Results of